vs

Side-by-side financial comparison of La Rosa Holdings Corp. (LRHC) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.

Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $20.2M, roughly 1.0× La Rosa Holdings Corp.). La Rosa Holdings Corp. runs the higher net margin — -27.4% vs -84.4%, a 57.0% gap on every dollar of revenue. On growth, La Rosa Holdings Corp. posted the faster year-over-year revenue change (3.2% vs -65.2%). Over the past eight quarters, La Rosa Holdings Corp.'s revenue compounded faster (72.5% CAGR vs 6.4%).

V. La Rosa and Sons Macaroni Company was founded in 1914 by Vincenzo La Rosa, a Sicilian immigrant. The company eventually became one of the largest regional brands in the United States producing over 40 varieties of pasta.

Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.

LRHC vs TRDA — Head-to-Head

Bigger by revenue
TRDA
TRDA
1.0× larger
TRDA
$20.6M
$20.2M
LRHC
Growing faster (revenue YoY)
LRHC
LRHC
+68.4% gap
LRHC
3.2%
-65.2%
TRDA
Higher net margin
LRHC
LRHC
57.0% more per $
LRHC
-27.4%
-84.4%
TRDA
Faster 2-yr revenue CAGR
LRHC
LRHC
Annualised
LRHC
72.5%
6.4%
TRDA

Income Statement — Q3 FY2025 vs Q1 FY2025

Metric
LRHC
LRHC
TRDA
TRDA
Revenue
$20.2M
$20.6M
Net Profit
$-5.5M
$-17.3M
Gross Margin
8.4%
Operating Margin
-24.7%
-106.0%
Net Margin
-27.4%
-84.4%
Revenue YoY
3.2%
-65.2%
Net Profit YoY
-125.7%
-173.8%
EPS (diluted)
$-5.44
$-0.42

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LRHC
LRHC
TRDA
TRDA
Q3 25
$20.2M
Q2 25
$23.2M
Q1 25
$17.5M
$20.6M
Q4 24
$17.7M
$37.4M
Q3 24
$19.6M
$19.6M
Q2 24
$19.1M
$94.7M
Q1 24
$13.1M
$59.1M
Q4 23
$41.8M
Net Profit
LRHC
LRHC
TRDA
TRDA
Q3 25
$-5.5M
Q2 25
$78.4M
Q1 25
$-95.7M
$-17.3M
Q4 24
$-5.1M
$1.1M
Q3 24
$-2.5M
$-14.0M
Q2 24
$-2.3M
$55.0M
Q1 24
$-4.6M
$23.5M
Q4 23
$-9.5M
Gross Margin
LRHC
LRHC
TRDA
TRDA
Q3 25
8.4%
Q2 25
8.0%
Q1 25
8.8%
Q4 24
8.9%
Q3 24
8.3%
Q2 24
8.3%
Q1 24
8.9%
Q4 23
Operating Margin
LRHC
LRHC
TRDA
TRDA
Q3 25
-24.7%
Q2 25
-10.6%
Q1 25
-26.7%
-106.0%
Q4 24
-17.1%
-15.7%
Q3 24
-8.9%
-110.7%
Q2 24
-9.7%
56.4%
Q1 24
-35.0%
35.7%
Q4 23
11.7%
Net Margin
LRHC
LRHC
TRDA
TRDA
Q3 25
-27.4%
Q2 25
337.8%
Q1 25
-546.5%
-84.4%
Q4 24
-28.7%
3.0%
Q3 24
-12.5%
-71.7%
Q2 24
-12.2%
58.1%
Q1 24
-35.1%
39.7%
Q4 23
-22.8%
EPS (diluted)
LRHC
LRHC
TRDA
TRDA
Q3 25
$-5.44
Q2 25
$15.25
Q1 25
$-5.86
$-0.42
Q4 24
$28.54
$-0.20
Q3 24
$-16.49
$-0.35
Q2 24
$-12.49
$1.55
Q1 24
$-0.35
$0.68
Q4 23
$-0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LRHC
LRHC
TRDA
TRDA
Cash + ST InvestmentsLiquidity on hand
$4.0M
$67.8M
Total DebtLower is stronger
$642.8K
Stockholders' EquityBook value
$1.6M
$417.3M
Total Assets
$21.7M
$486.5M
Debt / EquityLower = less leverage
0.41×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LRHC
LRHC
TRDA
TRDA
Q3 25
$4.0M
Q2 25
$5.1M
Q1 25
$2.9M
$67.8M
Q4 24
$1.4M
$101.2M
Q3 24
$1.8M
$78.0M
Q2 24
$1.6M
$185.3M
Q1 24
$1.1M
$68.4M
Q4 23
$67.6M
Total Debt
LRHC
LRHC
TRDA
TRDA
Q3 25
$642.8K
Q2 25
$644.3K
Q1 25
$645.9K
Q4 24
$647.6K
Q3 24
$649.2K
Q2 24
$650.8K
Q1 24
$652.4K
Q4 23
Stockholders' Equity
LRHC
LRHC
TRDA
TRDA
Q3 25
$1.6M
Q2 25
$3.4M
Q1 25
$-87.5M
$417.3M
Q4 24
$2.6M
$428.7M
Q3 24
$5.0M
$422.4M
Q2 24
$4.7M
$429.9M
Q1 24
$5.6M
$269.4M
Q4 23
$242.4M
Total Assets
LRHC
LRHC
TRDA
TRDA
Q3 25
$21.7M
Q2 25
$22.9M
Q1 25
$21.0M
$486.5M
Q4 24
$19.4M
$526.3M
Q3 24
$19.7M
$554.6M
Q2 24
$18.7M
$582.0M
Q1 24
$16.3M
$510.8M
Q4 23
$469.2M
Debt / Equity
LRHC
LRHC
TRDA
TRDA
Q3 25
0.41×
Q2 25
0.19×
Q1 25
Q4 24
0.25×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.12×
Q4 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LRHC
LRHC
TRDA
TRDA
Operating Cash FlowLast quarter
$-1.3M
$-38.5M
Free Cash FlowOCF − Capex
$-39.7M
FCF MarginFCF / Revenue
-192.9%
Capex IntensityCapex / Revenue
5.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-58.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LRHC
LRHC
TRDA
TRDA
Q3 25
$-1.3M
Q2 25
$-1.4M
Q1 25
$-3.5M
$-38.5M
Q4 24
$-1.1M
$-31.6M
Q3 24
$-591.6K
$-24.3M
Q2 24
$-803.1K
$39.8M
Q1 24
$-538.3K
$-25.5M
Q4 23
$-4.0M
Free Cash Flow
LRHC
LRHC
TRDA
TRDA
Q3 25
Q2 25
Q1 25
$-39.7M
Q4 24
$-32.2M
Q3 24
$-24.9M
Q2 24
$38.8M
Q1 24
$-26.4M
Q4 23
$-5.0M
FCF Margin
LRHC
LRHC
TRDA
TRDA
Q3 25
Q2 25
Q1 25
-192.9%
Q4 24
-86.2%
Q3 24
-127.3%
Q2 24
41.0%
Q1 24
-44.6%
Q4 23
-11.9%
Capex Intensity
LRHC
LRHC
TRDA
TRDA
Q3 25
Q2 25
Q1 25
5.6%
Q4 24
1.7%
Q3 24
3.3%
Q2 24
1.1%
Q1 24
1.4%
Q4 23
2.3%
Cash Conversion
LRHC
LRHC
TRDA
TRDA
Q3 25
Q2 25
-0.02×
Q1 25
Q4 24
-27.94×
Q3 24
Q2 24
0.72×
Q1 24
-1.09×
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LRHC
LRHC

Real Estate Residential Brokerage Services$16.8M83%
Transferred Over Time$3.5M17%

TRDA
TRDA

Segment breakdown not available.

Related Comparisons